The Liver Cancer Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Cancer (Primary Cancer, Secondary Cancer), By Type (Diagnostic, Therapeutics).
In 2024, the market for liver cancer diagnostics and therapeutics continues to evolve as a critical area of focus in oncology, given the rising global incidence and mortality rates associated with hepatocellular carcinoma (HCC) and other liver malignancies. Liver cancer poses significant challenges due to its often asymptomatic nature in early stages, leading to late diagnosis and limited treatment options. Diagnosis typically involves imaging modalities such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and liver biopsy, followed by staging assessments to guide treatment decisions. Therapeutic approaches for liver cancer include surgical resection, liver transplantation, locoregional therapies (such as radiofrequency ablation and transarterial chemoembolization), systemic chemotherapy, targeted therapies, and immunotherapy. Technological advancements in imaging techniques, molecular profiling, and minimally invasive treatment modalities have improved early detection rates and expanded treatment options, offering patients greater hope for improved outcomes and survival. With ongoing research into novel biomarkers, therapeutic targets, and personalized treatment strategies, the market for liver cancer diagnostics and therapeutics is poised for continued growth and innovation, driving advancements in early detection, precision medicine, and multimodal treatment approaches.
A prominent trend in the liver cancer market is the advancements in early detection and treatment modalities. With the increasing understanding of the molecular mechanisms underlying liver cancer development and progression, there is a growing emphasis on early diagnosis and intervention to improve patient outcomes. Innovative imaging techniques, such as contrast-enhanced ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, enable early detection of liver tumors and facilitate timely treatment initiation. Additionally, advancements in surgical techniques, including minimally invasive liver resection and ablative therapies such as radiofrequency ablation and microwave ablation, offer curative options for patients with early-stage liver cancer. The trend towards early detection and personalized treatment approaches drives market demand for innovative diagnostic tools and therapeutic interventions, leading to improved survival rates and quality of life for patients with liver cancer.
A key driver for the liver cancer market is the rising incidence of hepatitis B and C infections. Chronic hepatitis B and C viruses (HBV and HCV) are leading risk factors for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer. The global burden of chronic viral hepatitis remains high, particularly in regions with inadequate access to vaccination, screening, and treatment services. As a result, the prevalence of liver cirrhosis and liver cancer associated with chronic HBV and HCV infections continues to rise, driving the demand for liver cancer diagnostics, surveillance programs, and treatment modalities. The increasing awareness of viral hepatitis as a preventable cause of liver cancer, coupled with efforts to expand access to antiviral therapies and liver cancer screening, underscores the need for comprehensive strategies to combat the growing epidemic of liver cancer worldwide.
An emerging opportunity in the liver cancer market lies in the development of targeted therapies and immunotherapies. While surgical resection, liver transplantation, and locoregional therapies remain standard treatment options for early-stage liver cancer, advanced or unresectable liver tumors often require systemic therapy. The advent of targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, has transformed the treatment landscape for advanced HCC, offering new options for patients who are not candidates for surgery or locoregional therapies. Additionally, there is an opportunity for combination therapies that target multiple pathways involved in liver cancer progression, as well as novel immunotherapeutic approaches that harness the immune system to recognize and eliminate cancer cells. By investing in research and development of targeted therapies and immunotherapies, pharmaceutical companies can address unmet medical needs, improve patient outcomes, and capitalize on the growing market demand for effective systemic treatments for liver cancer, driving innovation and growth in the liver cancer therapeutics market.
Therapeutics for primary liver cancer represent the fast-growing segment within the liver cancer market. This growth is propelled by several factors. Firstly, primary liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), is a significant global health burden, with rising incidence rates attributed to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver diseases. The increasing prevalence of risk factors, coupled with the lack of effective early detection methods, underscores the critical need for innovative therapeutic interventions to improve patient outcomes. Additionally, advancements in cancer research have led to the development of targeted therapies, immunotherapies, and combination treatments that offer promising results in the management of primary liver cancer. Moreover, the emergence of novel treatment modalities such as radioembolization, ablative therapies, and molecularly targeted agents expands the therapeutic armamentarium, providing clinicians with more options to personalize treatment approaches based on tumor characteristics and patient profiles. Furthermore, the growing emphasis on multidisciplinary care and the integration of systemic therapies with locoregional treatments in liver cancer management further drives the demand for therapeutics. Overall, the convergence of rising disease burden, therapeutic innovations, and evolving treatment paradigms positions therapeutics for primary liver cancer as a key driver of growth within the liver cancer market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Bayer AG, Boston Scientific Corp, Bristol-Myers Squibb Company, Eli Lilly and Company, Exelixis Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Siemens Healthcare GmbH
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbott Laboratories
Bayer AG
Boston Scientific Corp
Bristol-Myers Squibb Company
Eli Lilly and Company
Exelixis Inc
F. Hoffmann-La Roche Ltd
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Siemens Healthcare GmbH
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Liver Cancer Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Liver Cancer Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Liver Cancer Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Liver Cancer Market Size Outlook, $ Million, 2021 to 2030
3.2 Liver Cancer Market Outlook by Type, $ Million, 2021 to 2030
3.3 Liver Cancer Market Outlook by Product, $ Million, 2021 to 2030
3.4 Liver Cancer Market Outlook by Application, $ Million, 2021 to 2030
3.5 Liver Cancer Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Liver Cancer Industry
4.2 Key Market Trends in Liver Cancer Industry
4.3 Potential Opportunities in Liver Cancer Industry
4.4 Key Challenges in Liver Cancer Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Liver Cancer Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Liver Cancer Market Outlook by Segments
7.1 Liver Cancer Market Outlook by Segments, $ Million, 2021- 2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
8 North America Liver Cancer Market Analysis and Outlook To 2030
8.1 Introduction to North America Liver Cancer Markets in 2024
8.2 North America Liver Cancer Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Liver Cancer Market size Outlook by Segments, 2021-2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
9 Europe Liver Cancer Market Analysis and Outlook To 2030
9.1 Introduction to Europe Liver Cancer Markets in 2024
9.2 Europe Liver Cancer Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Liver Cancer Market Size Outlook by Segments, 2021-2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
10 Asia Pacific Liver Cancer Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Liver Cancer Markets in 2024
10.2 Asia Pacific Liver Cancer Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Liver Cancer Market size Outlook by Segments, 2021-2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
11 South America Liver Cancer Market Analysis and Outlook To 2030
11.1 Introduction to South America Liver Cancer Markets in 2024
11.2 South America Liver Cancer Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Liver Cancer Market size Outlook by Segments, 2021-2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
12 Middle East and Africa Liver Cancer Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Liver Cancer Markets in 2024
12.2 Middle East and Africa Liver Cancer Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Liver Cancer Market size Outlook by Segments, 2021-2030
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Bayer AG
Boston Scientific Corp
Bristol-Myers Squibb Company
Eli Lilly and Company
Exelixis Inc
F. Hoffmann-La Roche Ltd
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Siemens Healthcare GmbH
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Cancer
Primary Cancer
-Hepatocellular Carcinoma
-Hepatoblastoma
-Others
Secondary Cancer
-Hemangioma
-Hepatic adenoma
-Others
By Type
Diagnostic
-Ultrasound Scans
-Confirmatory Needle Biopsy
-Endoscopic Ultrasound
-CT scan
-PET Scan
-Others
Therapeutics
-Targeted Therapy
-Radiation Therapy
-Immunotherapy
-Chemotherapy
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Liver Cancer Market is one of the lucrative growth markets, poised to register a 8.3% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott Laboratories, Bayer AG, Boston Scientific Corp, Bristol-Myers Squibb Company, Eli Lilly and Company, Exelixis Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Siemens Healthcare GmbH
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume